The healthcare sector is registering itself as an impressive sector, which is evident from the rally in most of the players in the space. Among all, Vascular Solutions, Inc. (NASDAQ:VASC) too is claiming a brighter spot as it continues to gain traction among the investors. The stock of the medical device company rose by 0.07% to $28.68 during the previous trading session.
Upbeat Q4 results
The company had released its latest earnings just a month back, where it reported as much as 20% growth in its net income during the fourth quarter. At the same time, most of the prominent figures were up substantially implying that the company is doing better-than-expected. The revenues of Vascular Solutions, Inc. (NASDAQ:VASC) in the fourth quarter came in at $33.6 million, indicating 15.6% growth year-over-year that surpassed the analysts’ estimates of $33.19 million.
Also, the company reported earnings per share of $0.23 against the Street forecast of $0.19 EPS. Both the operating income and the net income of the company increased by 12.8% and 20% to $5.3 million and $4.2 million respectively. The company reported full-year revenues of $126.1 million and EPS of $0.72 for the financial year 2014.
Guidance for the FY 2015 and FQ1
Other than this, the company also released guidance for the fiscal year 2015 as well as the first quarter. In its press release, Vascular Solutions, Inc. (NASDAQ:VASC) guided the revenues in the range of $139-$143 million while estimated EPS in between $0,88-$0.92 for the fiscal year 2015. For the first quarter, the company expects revenues to come in between $33-$34 million and EPS in the range of $0.16-$0.18.
In addition, Vascular Solutions, Inc. (NASDAQ:VASC) has added one more achievement under its belt. The company has recently replaced MWI Veterinary Supply (MWIV) in the S&P SmallCap 600 Index with effect from February 23, 2015.
Vascular Solutions, Inc. (NASDAQ:VASC) is currently trading at $28.26 after losing 1.46%.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: